Novartis wins 1st cell-culture flu vaccine OK in US with Flucelvax
This article was originally published in Scrip
Executive Summary
The US government's nearly $500 million investment in a first-of-its-kind vaccine manufacturing facility in North Carolina paid off with the US FDA's approval on 20 November of Novartis' Flucelvax, the first cell-culture vaccine in the US intended to protect against seasonal influenza.